Mesoblast’s allogeneic or ‘off-the-shelf’ regenerative medicine products focus on repair of damaged tissues and modulation of inflammatory responses in conditions with significant unmet medical needs.


Mesoblast’s cell-based core technologies include its highly purified, immunoselected Mesenchymal Precursor Cells (MPCs), culture-expanded Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs). Mesoblast’s protein technologies are based on factors derived from its proprietary cellular platforms, including Stromal Derived Factor-1 (SDF-1).

Product Pipeline

Mesoblast is developing a range of products derived from the Company’s proprietary Mesenchymal Cell Lineage technology platforms. Mesoblast’s product development focus is in four major and distinct areas:

Latest News

View all announcements


  • 25/26 August 2014 - Mesoblast will hold a telecon to discuss its 12-month results for the FY ended 30 June 2014. Details are: USA 25 August @ 2030 ET, and Australia, 26 August @ 1030 AEST. A live webcast of the call will be available here.